en عمومى General پژوهشي Original article <div><strong>Background and Aims:</strong> Human T-lymphotropic virus type 1 (HTLV-1), is as a type C retrovirus, which was first isolated from a patient with Adult T-cell leukemia/lymphoma (ATLL). Approximately 10-20 million people are infected by HTLV-1 virus worldwide, but only 5-10% of them develop clinical manifestations such as Acute-T lymphoma (ATL), HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP), uveitis, and infective dermatitis. Indinavir was the first protease inhibitor used for treating HIV-1. It has some activity on HTLV-1, but it is not fully able to inhibit the HTLV-1 protease. Nowadays, design and construction of novel pharmacophore compounds can serve as an appropriate replacement for Indinavir.&nbsp;<br> <strong>Materials and Methods:</strong> In the present research, we used bioinformatics studies, to evaluate the potential role of four novel pharmacophres with inhibitory function on HTLV-1 protease, so called KMI pharmacophores (Keikha Modified Indinavir).<br> <strong>Results:</strong> After a detailed structural analysis of each of them, it seems all four designed phamacophores, (especially KMI-3) could be more effective on HTLV-1 protease than Indinavir.<br> <strong>Conclusions: </strong>According to exact in silico evaluations of each four pharmacophores, KMI-3 demonstrated a potential for its use on treatment of HTLV-1 infections.&nbsp;</div> HTLV-1, Protease, Indinavir, Molecular docking 16 23 http://journal.isv.org.ir/browse.php?a_code=A-10-224-4&slc_lang=en&sid=1 masoud youssefi youssefim@mums.ac.ir 10031947532846007038 10031947532846007038 No Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Antimicrobial Resistance Research center Mashhad University of Medical Sciences, Mashhad, Iran. kiarash ghazvini ghazvinik@mums.ac.ir 10031947532846007039 10031947532846007039 No Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Antimicrobial Resistance Research center Mashhad University of Medical Sciences, Mashhad, Iran. Carlos Brites abba@gmail.com 10031947532846007040 10031947532846007040 No LAPI, Laboratório de Pesquisa em Infectologia, Department of Medicine, Complexo Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Brazil. Mohsen Karbalaei abba@gmail.com 10031947532846007041 10031947532846007041 No Department of Microbiology and Virology, School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran masoud keikha masoud.keykha90@gmail.com 10031947532846007042 10031947532846007042 Yes Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Antimicrobial Resistance Research center Mashhad University of Medical Sciences, Mashhad, Iran.